ArticleAdvances in radiation oncology
Dosimetric Evaluation of PSMA PET-Delineated Dominant Intraprostatic Lesion Simultaneous Infield Boosts.
Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- Outcomes of pelvic radiotherapy with boost strategies in high nodal-risk prostate cancer: A phase 2 prospective trial.Clinical and translational radiation oncology · 2026Article
- Implications for Radiation Microboosting Based on Pathology Correlations With Prostate-Specific Membrane Antigen and Multiparametric Magnetic Resonance Imaging Findings.Advances in radiation oncology · 2026Article
- Clinical Impact of PSMA PET Fusion-Based RT Planning on Dosimetry and PSA Response in Prostate Cancer.Journal of clinical medicine · 2026Article
- Article
- Article
- Framework to calculateMedical physics · 2025Article
- A review of artificial intelligence in brachytherapy.Journal of applied clinical medical physics · 2025Review
- Review
- A proof-of-concept study of personalized dosimetry for targeted radioligand therapy using pre-treatment diagnostic dynamic PET/CT and Monte Carlo simulation.Frontiers in oncology · 2025Article
- Article
- Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) of prostate cancer: current and emerging applications.Abdominal radiology (New York) · 2024Review
- Dose differentiated high-dose-rate prostate brachytherapy: a feasibility assessment of MRI-guided dose escalation to dominant intra-prostatic lesions.Journal of contemporary brachytherapy · 2022Article
- Feasibility of biology-guided radiotherapy using PSMA-PET to boost to dominant intraprostatic tumour.Clinical and translational radiation oncology · 2022Article
- Proton therapy for prostate cancer: current state and future perspectives.The British journal of radiology · 2022Review
- Imaging Biomarkers in Prostate Stereotactic Body Radiotherapy: A Review and Clinical Trial Protocol.Frontiers in oncology · 2022Article
- Value of 18F-fluorocholine PET/CT in predicting response to radical radiotherapy in patients with localized prostate cancer.Clinical and translational radiation oncology · 2021Article
- Intraprostatic Tumor Segmentation on PSMA PET Images in Patients with Primary Prostate Cancer with a Convolutional Neural Network.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Influence of Urethra Sparing on Tumor Control Probability and Normal Tissue Complication Probability in Focal Dose Escalated Hypofractionated Radiotherapy: A Planning Study Based on Histopathology Reference.Frontiers in oncology · 2021Article
- Prostate cancer tumour control probability modelling for external beam radiotherapy based on multi-parametric MRI-GTV definition.Radiation oncology (London, England) · 2020Article
- Comparison of Manual and Semi-Automatic [Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeProstate cancer is multifocal. However, there often exists a single dominant focus in the gland responsible for driving the biology of the disease. Dose escalation to the dominant lesion is a proposed strategy to increase tumor control. We applied radiobiological modeling to evaluate the dosimetric feasibility and benefit of dominant intraprostatic lesion simultaneous in-field boosts (DIL-SIB) to the gross tumor volume (GTV), defined using a novel molecular positron emission tomography (PET) probe (18F-DCFPyL) directed against prostate specific membrane antigen (PSMA). METHODS AND MATERIALS: Patients with clinically localized, biopsy-proven prostate cancer underwent preoperative [
resultsComparative DIL-SIB plans for 6 men were generated from preoperative [
conclusionsPSMA PET provides a novel approach to define GTV for SIB-DIL dose escalation. Work is ongoing to validate PSMA PET-delineated GTV through correlation to coregistered postprostatectomy digitized histopathology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.